These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36174850)

  • 21. Systems Biology and Peptide Engineering to Overcome Absorption Barriers for Oral Peptide Delivery: Dosage Form Optimization Case Study Preceding Clinical Translation.
    Tyagi P; Patel C; Gibson K; MacDougall F; Pechenov SY; Will S; Revell J; Huang Y; Rosenbaum AI; Balic K; Maharoof U; Grimsby J; Subramony JA
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral delivery of peptide drugs: barriers and developments.
    Hamman JH; Enslin GM; Kotzé AF
    BioDrugs; 2005; 19(3):165-77. PubMed ID: 15984901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.
    Aguirre TA; Teijeiro-Osorio D; Rosa M; Coulter IS; Alonso MJ; Brayden DJ
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):223-241. PubMed ID: 26921819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics.
    Kanugo A; Misra A
    Ther Deliv; 2020 Nov; 11(11):713-732. PubMed ID: 33225869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of intranasally delivered peptides: key considerations for pharmaceutical development.
    Al Bakri W; Donovan MD; Cueto M; Wu Y; Orekie C; Yang Z
    Expert Opin Drug Deliv; 2018 Oct; 15(10):991-1005. PubMed ID: 30173579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral delivery of peptides and proteins using lipid-based drug delivery systems.
    Li P; Nielsen HM; Müllertz A
    Expert Opin Drug Deliv; 2012 Oct; 9(10):1289-304. PubMed ID: 22897647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation strategies to improve oral peptide delivery.
    Maher S; Ryan B; Duffy A; Brayden DJ
    Pharm Pat Anal; 2014 May; 3(3):313-36. PubMed ID: 24998290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral peptide and protein delivery: intestinal obstacles and commercial prospects.
    Smart AL; Gaisford S; Basit AW
    Expert Opin Drug Deliv; 2014 Aug; 11(8):1323-35. PubMed ID: 24816134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.
    Aungst BJ
    J Pharm Sci; 1993 Oct; 82(10):979-87. PubMed ID: 8254497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation strategies to improve the efficacy of intestinal permeation enhancers
    Maher S; Brayden DJ
    Adv Drug Deliv Rev; 2021 Oct; 177():113925. PubMed ID: 34418495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transmembrane transport of peptide type compounds: prospects for oral delivery.
    Lipka E; Crison J; Amidon GL
    J Control Release; 1996 May; 39(2-3):121-9. PubMed ID: 11539926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic analysis of chemical permeation enhancers for oral drug delivery.
    Whitehead K; Mitragotri S
    Pharm Res; 2008 Jun; 25(6):1412-9. PubMed ID: 18311478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction for the special issue on recent advances in drug delivery across tissue barriers.
    Mrsny RJ; Brayden DJ
    Tissue Barriers; 2016; 4(2):e1187981. PubMed ID: 27358759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size.
    Fein KC; Gleeson JP; Newby AN; Whitehead KA
    Eur J Pharm Biopharm; 2022 Jan; 170():70-76. PubMed ID: 34879228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.
    Perucca E; Bialer M
    CNS Drugs; 2020 Aug; 34(8):795-800. PubMed ID: 32504461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.
    Beg S; Swain S; Rizwan M; Irfanuddin M; Malini DS
    Curr Drug Deliv; 2011 Nov; 8(6):691-702. PubMed ID: 21864253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs.
    Yamamoto A; Ukai H; Morishita M; Katsumi H
    Pharmacol Ther; 2020 Jul; 211():107537. PubMed ID: 32201316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery.
    Karavasili C; Spanakis M; Papagiannopoulou D; Vizirianakis IS; Fatouros DG; Koutsopoulos S
    J Pharm Sci; 2015 Jul; 104(7):2304-11. PubMed ID: 25994901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New perspectives in oral peptide delivery.
    Zizzari AT; Pliatsika D; Gall FM; Fischer T; Riedl R
    Drug Discov Today; 2021 Apr; 26(4):1097-1105. PubMed ID: 33497830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.